Aranidipine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H20N2O7 |
Molar mass | 388.376 g·mol−1 |
3D model (JSmol) | |
| |
InChI
| |
Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.[1]
References[]
- ^ "Aranidipine". PubMed. Retrieved 23 December 2018.
Categories:
- Drugs not assigned an ATC code
- Calcium channel blockers
- Dihydropyridines
- Carboxylate esters
- Ketones
- Nitrobenzenes
- Methyl esters
- Cardiovascular system drug stubs